GeneSpector Innovations presents a novel, patent-protected treatment method for HIV infections utilizing heme arginate, which is a known compound currently used in treatment of acute attacks of hepatic porphyria.

It has been clinically proven by in vivo testing in HIV+ patients that application of heme arginate in standard therapeutic dosing leads to a significant reduction of latent viral reservoir, i.e. overall number of infected T-cells, while being safe and well tolerated by the patient. Application of just one dose leads to a reduction of the latent reservoir by one third within two weeks. It also stimulates patient’s immune system and causes expression of viral proteins in the infected cells, thus making them visible for the activated immune system and leading to natural elimination of infected T-cells.

Therapy combining heme arginate with suitable antiretroviral drugs preventing dissemination of the reactivated virus has the potential to not only suppress HIV infection, but to completely cure the patient removing the laten viral reservoir from infected T lymphocytes.